UBS Group to Expand U.S. Wealth Operations After Securing OCC Approval – March 23, 2026
Key Takeaways UBS received OCC approval to convert UBS Bank USA into a nationally chartered bank, expanding services.UBS…
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal – March 6, 2026
Key Takeaways Roche’s phase II ZUPREME-1 met its primary endpoint as petrelintide drove significant weight loss vs. placebo.Roche…
The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT – February 25, 2026
For Immediate Release Chicago, IL – February 25, 2026 – Zacks.com announces the list of stocks featured in…
Roche’s BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study – March 3, 2026
Key Takeaways RHHBY’s phase III FENhance 1 met its primary endpoint in relapsing MS.Fenebrutinib cut RMS relapses 51%…
The Zacks Analyst Blog Highlights NVIDIA, Roche, Lam Research, Tredegar and Kewaunee Scientific – October 17, 2025
For Immediate Release Chicago, IL – October 17, 2025 – Zacks.com announces the list of stocks featured in…
The Zacks Analyst Blog Highlights Roche, Linde, Disney and Vaso – September 16, 2025
For Immediate Release Chicago, IL – September 16, 2025 – Zacks.com announces the list of stocks featured in…
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US – May 13, 2025
Less than a month after announcing a $50 billion investment in its U.S. operations over the next five…
RHHBY’s Sales Up 7% in First 9 Months of 2025, ’25 Earnings View Raised – October 23, 2025
Key Takeaways Roche’s sales hit CHF 45.9B for the first nine months of 2025, up 7% at constant…
UBS Group to Add 3,000 Jobs in India Amid Credit Suisse Integration – February 12, 2026
Key Takeaways UBS will add 2,000-3,000 roles in Hyderabad to strengthen tech and operations capabilities.Job cuts in Switzerland…
The Zacks Analyst Blog Highlights Micron Technology, Roche and UnitedHealth – January 8, 2026
For Immediate Release Chicago, IL – January 8, 2026 – Zacks.com announces the list of stocks featured in…
Roche Reports Upbeat Efficacy Data From Phase II Obesity Study – January 28, 2026
Key Takeaways Roche reported robust, placebo-adjusted weight loss up to 22.5% at 48 weeks with once-weekly CT-388.RHHBY said…